Prognostic Impact of Proteolytic Factors ( Urokinase-Type Plasminogen Activator , Plasminogen Activator Inhibitor 1 , and Cathepsins B , D , and L ) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy 1

@inproceedings{Harbeck2001PrognosticIO,
  title={Prognostic Impact of Proteolytic Factors ( Urokinase-Type Plasminogen Activator , Plasminogen Activator Inhibitor 1 , and Cathepsins B , D , and L ) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy 1},
  author={Nadia Harbeck and Uta Alt and Ursula Berger and Achim Kr{\"u}ger and Christoph Thomssen and F. J{\"a}nicke and Heinz Hoefler and Ronald E. Kates and Manfred Schmitt},
  year={2001}
}
Purpose: Prognostic and predictive impact of five proteolytic factors associated with tumor invasion and metastasis in primary breast cancer were evaluated after longterm follow-up. Experimental Design: Antigen levels of urokinase-type plasminogen activator, plasminogen activator inhibitor-1 (PAI-1), Cathepsins B, D, and L were determined using immunochemical assays in primary tumor tissue of 276 patients. Results: During follow-up (median 109 months), 119 (43%) patients relapsed, and 117 (42… CONTINUE READING

4 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
Experimental Design : Antigen levels of urokinase - type plasminogen activator , plasminogen activator inhibitor-1 ( PAI-1 ) , Cathepsins B , D , and L were determined using immunochemical assays in primary tumor tissue of 276 patients .
All Topics